Ethical perspectives in neurology: Ethical considerations when doctor and patient perspectives on treatment risks differ

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 234-237

  Conway, Jill ^a   Kachuck, Norman J ^a  

^a EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NATALIZUMAB; STEROID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BIOETHICS; BRAIN TOXICITY; CASE REPORT; CONFLICT OF INTEREST; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ETHICS; FEMALE; FOLLOW UP; HUMAN; INFORMED CONSENT; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PATIENT AUTONOMY; PERSONAL AUTONOMY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION;

EID: 78650740750     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389947.12477.85     Document Type: Article

References (3)

1. Polman CH, O'Connor PW, Havrdova E, et al; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM 2006;354(9):899-910.
2. American Academy of Neurology Professional Association. Code of Professional Conduct. Available at www.aan.com/globals/axon/assets/3968.pdf. Updated March 7, 2008. Accessed July 20, 2010.
3. 42 CFR §411.350-§411.389. Available at http://ecfr.gpoaccess. gov/cgi/t/text/text-idx?c=ecfr&sid= 55974484b37410b7d65ccd9c749ec5fc& rgn=div6&view=text&node=42:2.0.1.2.11.10&idno=42.